Lundbeck preps phase 3 for migraine prevention drug Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

#Lundbeck #phase3 #migraineprevention #migrainepreventiondrug #bocunebart #antiPACAPantibody #phase2b #PROCEEDtrial #intravenousbocunebart #LuAG09222 #monthlymigrainedays #MMD #PACAP #neuropeptide #pathophysiologyofmigraine #migrainetreatment #PACAPpathway #migrainepreventionmarket
zurl.co/M7FHE

Lundbeck unveils migraine data for eptinezumab at international congress - PharmaTimes New phase 4 results show sustained symptom relief and improved patient outcomes

#neurology #drugdevelopment #Lundbeck #migraine #eptinezumab #migarinesymptomrelief #patientoutcomes #InternationalHeadacheCongress #migrainepatients #chronicmigraine #RESOLUTIONclinicaltrial #SUNSETclinicaltrial #medicationoveruseheadache #monthlymigrainedays #MMDs
zurl.co/LE6FP

Lundbeck unveils migraine data for eptinezumab at international congress - PharmaTimes New phase 4 results show sustained symptom relief and improved patient outcomes

#neurology #drugdevelopment #Lundbeck #migraine #eptinezumab #migarinesymptomrelief #patientoutcomes #InternationalHeadacheCongress #migrainepatients #chronicmigraine #RESOLUTIONclinicaltrial #SUNSETclinicaltrial #medicationoveruseheadache #monthlymigrainedays #MMDs
zurl.co/HStkM